Replaces Prod. #: BML-CN200
Competitive inhibitor of soluble guanylyl cyclase (sGC) (IC50=2µM) and of cGMP production. Neurotoxin. Blocks antigen-induced leukotriene release and reduces platelet-endothelial cell adhesion. Blocks acethylcholine-induced vasorelaxation.
Product Details
| Alternative Name: | 6-(Phenylamino)-5,8-quinolinedione, 6-Anilino-5,8-quinolinedione |
| |
| Formula: | C15H10N2O2 |
| |
| MW: | 250.3 |
| |
| Source: | Synthetic. |
| |
| CAS: | 91300-60-6 |
| |
| Purity: | ≥95% (TLC) |
| |
| Identity: | Determined by 1H-NMR. |
| |
| Appearance: | Violet to dark red powder. |
| |
| Solubility: | Soluble in methanol, methylene chloride or diluted aqueous acid; insoluble in water. |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | -20°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
The effects of intracerebroventricular application of 8-Br-cGMP and LY-83,583, a guanylyl cyclase inhibitor, on sleep-wake activity in rats: A.C. Ribeiro & L. Kapas; Brain Res.
1049, 25 (2005),
Abstract;
LY-83583 stimulates glucose transporter-1-mediated glucose transport independent of changes in cGMP levels: R.K. Prasad, et al.; Eur. J. Pharmacol.
366, 101 (1999),
Abstract;
Nitric oxide stimulates cGMP production and mimics synaptic responses in metacerebral neurons of Aplysia: H.Y. Koh and J.W. Jacklet; J. Neurosci.
19, 3818 (1999),
Abstract;
Full Text
Guanylyl cyclase inhibition reduces contractility and decreases cGMP and cAMP in isolated rat hearts: R.E. Klabunde, et al.; Cardiovasc. Res.
37, 676 (1998),
Abstract;
Histochemical detection of quinone reductase activity in situ using LY 83583 reduction and oxidation: T.H. Murphy, et al.; J. Neurochem.
70, 2156 (1998),
Abstract;
Inhibition of nitric oxide formation and superoxide generation during reduction of LY83583 by neuronal nitric oxide synthase: Y. Kumagai, et al.; Eur. J. Pharmacol.
360, 213 (1998),
Abstract;
A comparative study of the effects of three guanylyl cyclase inhibitors on the L-type Ca2+ and muscarinic K+ currents in frog cardiac myocytes: N. Abi-Gerges, et al.; Br. J. Pharmacol.
121, 1369 (1997),
Abstract;
Modification by LY 83583 and methylene blue of relaxation induced by nitric oxide, glyceryl trinitrate, sodium nitroprusside and atriopeptin in aortae of the rat, guinea-pig and rabbit: T. Kawada, et al.; Gen. Pharmacol.
25, 1361 (1994),
Abstract;
Interleukin 1 induces prolonged L-arginine-dependent cyclic guanosine monophosphate and nitrite production in rat vascular smooth muscle cells: D. Beasley, et al.; J. Clin. Invest.
87, 602 (1991),
Abstract;
LY 83583 interferes with the release of endothelium-derived relaxing factor and inhibits soluble guanylate cyclase: A. Mülsch, et al.; J. Pharmacol. Exp. Ther.
247, 283 (1988),
Abstract;
Pharmacologic analysis of two novel inhibitors of leukotriene (slow reacting substance) release: J.H. Fleisch, et al.; J. Pharmacol. Exp. Ther.
229, 681 (1984),
Abstract;
General Literature References
LY 83583 (6-anilino-5,8-quinolinedione) blocks nitrovasodilator-induced cyclic GMP increases and inhibition of platelet activation: A. Mulsch, et al.; Naunyn-Schmiedeberg's Arch. Pharmacol.
340, 119 (1989),
Abstract;
Evidence that cGMP is the mediator of endothelium-dependent inhibition of contractile responses of rat arteries to alpha-adrenoceptor stimulation: K.M. MacLeod, et al.; Mol. Pharmacol.
32, 59 (1987),
Abstract;
